Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | DRD3 | P35462 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22355540 | 1.00 | ESR1 (0.52) | ESR1ESR2CYP26A1OPRK1DRD2 | |
| SCHEMBL30616504 | 1.00 | ESR1 (0.52) | ESR1ESR2CYP26A1OPRK1DRD2 | |
| SCHEMBL29791484 | 1.00 | ESR1 (0.52) | ESR1ESR2CYP26A1OPRK1DRD2 | |
| SCHEMBL225583 | 0.93 | ESR1 (0.46) | ESR1ESR2CYP26A1OPRK1DRD2 | |
| SCHEMBL226147 | 0.91 | DRD2 (0.52) | CYP26A1DRD2DRD3CA1CA2 | |
| SCHEMBL224545 | 0.90 | CYP26A1 (0.50) | ESR1ESR2CYP26A1OPRK1DRD2 | |
| SCHEMBL227769 | 0.87 | OPRK1 (0.57) | ESR1ESR2OPRK1DRD2DRD3 | |
| SCHEMBL15888956 | 0.86 | ESR2 (0.52) | ESR1ESR2CYP26A1OPRK1DRD2 | |
| SCHEMBL15888978 | 0.86 | ESR2 (0.52) | ESR1ESR2CYP26A1OPRK1DRD2 | |
| SCHEMBL227938 | 0.85 | DRD2 (0.60) | DRD2DRD3CA1CA2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117902990-A | Preparation method of ilalastine intermediate (R) -6- (2-amino-4-methoxyphenyl) -5,6,7, 8-tetrahydronaphthalene-2-ol | 海化生命(厦门)科技有限公司 | 2024-04-19 | — | — | CN | claimed |
| CN-116969848-A | Preparation method of intermediate of drug for treating advanced breast cancer | 北京康立生医药技术开发有限公司 | 2023-10-31 | — | — | CN | claimed |
| US-20260008792-A1 | PROCESSES AND COMPOUNDS | RADIUS PHARMACEUTICALS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12441745-B2 | Processes and compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| CN-117902990-A | Preparation method of ilalastine intermediate (R) -6- (2-amino-4-methoxyphenyl) -5,6,7, 8-tetrahydronaphthalene-2-ol | 海化生命(厦门)科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117902990-A | Preparation method of ilalastine intermediate (R) -6- (2-amino-4-methoxyphenyl) -5,6,7, 8-tetrahydronaphthalene-2-ol | 海化生命(厦门)科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117902990-A | Preparation method of ilalastine intermediate (R) -6- (2-amino-4-methoxyphenyl) -5,6,7, 8-tetrahydronaphthalene-2-ol | 海化生命(厦门)科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-116969848-A | Preparation method of intermediate of drug for treating advanced breast cancer | 北京康立生医药技术开发有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116969848-A | Preparation method of intermediate of drug for treating advanced breast cancer | 北京康立生医药技术开发有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20220162233-A1 | PROCESSES AND COMPOUNDS | RADIUS HEALTH, INC. | 2022-05-26 | — | — | US | disclosed |
| US-20220162233-A1 | PROCESSES AND COMPOUNDS | RADIUS HEALTH, INC. | 2022-05-26 | — | — | US | disclosed |
| US-7960412-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | RADIUS HEALTH, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | RADIUS HEALTH, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | RADIUS HEALTH, INC. | 2009-12-31 | — | — | US | disclosed |
| US-7612114-B2 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-7612114-B2 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-7612114-B2 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI CO., LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
| EP-1577288-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Eisai Co., Ltd. (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885CYP26A1 459/4885 |
| US-12441745-B2 | Processes and compounds | ESR1, ESR2, CYP19A1 | ESR1 1/4885ESR2 2/4885CYP26A1 33/4885 |
| US-20260008792-A1 | PROCESSES AND COMPOUNDS | ESR1, ESR2, PGR | ESR1 1/4885ESR2 2/4885CYP26A1 76/4885 |
| US-20220162233-A1 | PROCESSES AND COMPOUNDS | ESR1, ESR2, CYP19A1 | ESR1 1/4885ESR2 2/4885CYP26A1 33/4885 |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | BRCA1, BCR, RCC1 | ESR1 34/4885ESR2 21/4885CYP26A1 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.